Post-Marketing Surveillance of Euhypnos® (Temazepam): A New Hypnotic
Author:
- 1 July 1980
- journal article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 8 (4) , 295-299
Abstract
A post-marketing surveillance study of Euhypnos (temazepam), a new short-acting benzodiazepine hypnotic. A total of 12,350 patients requiring a sleep inducer were treated for up to 3 months with doses of 10–30 mg at night. After 2 weeks 80% of First Reports (FRs) rated Euhypnos effective and at 3 months this had risen to 92% of 3062 Second Reports (SRs). Hangover was reported in 7% of FRs and 2% of SRs but in general the drug was well tolerated with adverse reactions consisting mainly of morning nausea, headache, drowsiness and vivid dreaming. Eighty-seven per cent of FRs and 93% of SRs were ‘Clean’ reporting no hangover, adverse reaction or event of any kind.Keywords
This publication has 4 references indexed in Scilit:
- Euhypnos® Forte (Temazepam) for Resistant Insomnia: Post-Marketing Surveillance, an Interim ReportJournal of International Medical Research, 1979
- Post-marketing surveillance of adverse reactions to new medicines.BMJ, 1977
- Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"?BMJ, 1977
- Monitoring adverse reactions to drugs.BMJ, 1977